Keyword: Boehringer Ingelheim
Boehringer has moved its pan-KRAS inhibitor into phase 1 trials, both on its own and in combination with Novartis’ MEK inhibitor Mekinist.
The series A round sets Abalos up to generate anti-tumoral virus strains and take them toward testing in humans.
Short for Machine Learning Ledger Orchestration for Drug Discovery, the three-year project from the Innovative Medicines Initiative hopes to build an AI platform capable of ingesting large libraries of proprietary information while protecting its confidentiality.
Boehringer Ingelheim shuffles board, senior management; Medtronic CEO Ishrak set to retire in 2020; Zealand appoints Dallas to CFO role.
Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.
Boehringer Ingelheim is licensing an autotaxin inhibitor from Bridge Biotherapeutics for €45 million and promising more than €1 billion in biobucks.
German pharma Boehringer Ingelheim is putting a few hundred million euros on the table to snap up Swiss cancer biotech Amal Therapeutics.
Boehringer Ingelheim is licensing a biologic from South Korea’s Yuhan for $40 million upfront and promising up to $830 million in milestones.
In addition to a $47.5 million upfront payment from Eli Lilly, Centrexion could net up to $950 million in development, regulatory and sales milestones.
Two months of treatment with the diabetes drug Jardiance reduced pulmonary congestion and biomarkers of heart failure in pig models.